Allergy Therapeutics (AGY)

 

Latest News

Allergy Therapeutics to present on 7 March 2018 at the Shares and AJ Bell Spotlight Evening in London

If you are looking for some investment ideas for your ISA, then come along the Shares and AJ Bell Investor Evening in Lo...

Allergy completes recruitment in grass allergy study, results due ahead of expectations

Allergy Therapeutics plc announced Monday that recruitment has been completed in its grass allergy Phase II study with r...

Completion of recruitment in PQ Grass Ph II trial

RNS Number: 5209E Allergy Therapeutics PLC 12 February 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Completion of recruitment in PQ Grass Phase II trial Trial running ahead of schedule with data now due in early H2 2018 12 February 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specia...

Hardman Research: Growth in a tough market

RNS Number: 7100D Allergy Therapeutics PLC 02 February 2018 Hardman Research: Growth in a tough market Growth in a tough market: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in th...

All News

DateHeadlineSource
15-02-18Allergy Therapeutics to present on 7 March 2018 at the Shares and AJ Bell Spotlight Evening in LondonStockMarketWire
12-02-18Allergy completes recruitment in grass allergy study, results due ahead of expectationsStockMarketWire
12-02-18Completion of recruitment in PQ Grass Ph II trialRNS
02-02-18Hardman Research: Growth in a tough marketRNS
31-01-18Allergy Therapeutics first-half revenue rises 4.4%StockMarketWire
31-01-18Trading UpdateRNS
10-01-18Holdings in CompanyRNS
09-01-18Allergy Therapeutics completes recruitment for clinical study StockMarketWire
09-01-18PQ Birch Phase III trial completes recruitmentRNS
12-12-17Allergy Therapeutics co-development agreement with Ergomed StockMarketWire
12-12-17Co-development agreement with Ergomed plcRNS
07-12-17Holding(s) in CompanyRNS
22-11-17All resolutions passed at AGM of Allergy TherapeuticsStockMarketWire
22-11-17Result of AGMRNS
21-11-17Block Listing ApplicationRNS
13-11-17Allergy Therapeutics to Present at Jefferies 2017RNS
07-11-17Director/PDMR ShareholdingRNS
07-11-17Director/PDMR ShareholdingRNS
19-10-17Publication of Annual Report and notice of AGMRNS
19-10-17Allergy Therapeutics starts dosing for grass pollen trial StockMarketWire
19-10-17Commencement of dosing in PQ Grass Phase II TrialRNS
12-10-17Holding(s) in CompanyRNS
12-10-17Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
12-10-17Director/PDMR ShareholdingRNS
10-10-17Allergy Therapeutics 'continuing to gain market share'StockMarketWire
10-10-17Hardman Research: Continuing to gain market shareRNS
28-09-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
28-09-17Allergy Therapeutics pre-tax losses narrow StockMarketWire
28-09-17Preliminary ResultsRNS
18-09-17Allergy Therapeutics gets approval for PQ Grass trial StockMarketWire
18-09-17Approval for PQ Grass Phase II trialRNS
11-09-17Allergy Therapeutics expands R&D and clinical team StockMarketWire
11-09-17Expansion of Clinical Development and R&D teamsRNS
15-08-17 Allergy Therapeutics schedules FY results StockMarketWire
15-08-17Notice of ResultsRNS
18-07-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
18-07-17Allergy Therapeutics ahead of forecasts StockMarketWire
18-07-17Trading UpdateRNS
06-07-17Publication of adjuvant studies in journalsRNS
27-06-17Investor and analyst site visitsRNS

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account